We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
LACREO (Sun Pharma ANZ Pty Ltd)
Product name
LACREO
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
143 (255 working days)
Active ingredients
lanreotide acetate
Registration type
New generic medicine
Indication
TRADE NAME is indicated for:
- the treatment of acromegaly when the circulating levels of growth hormone and IGF-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory
- the treatment of symptoms of carcinoid syndrome associated with carcinoid (neuroendocrine) tumours
- the treatment of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adult patients with unresectable locally advanced or metastatic disease.